Saccomano Nicholas A 4

What Happened

• Nicholas A. Saccomano, President & CEO and a director of OnKure Therapeutics (OKUR), had 86 shares disposed on June 22, 2026. The shares were sold at a weighted average price of $4.40 per share for total proceeds of about $378.
• The sale was an automatic "sell to cover" tied to the vesting of restricted stock units (RSUs), i.e., shares were sold to satisfy tax withholding obligations rather than an open-market investment decision.

Key Details

• Transaction date: 2026-06-22; filing date: 2026-06-24 (timely Form 4).
• Price: weighted average $4.40; individual trade prices ranged $4.27–$4.54 (multiple trades per filing footnote).
• Proceeds: approximately $378.
• Shares owned after transaction: not specified in the filing.
• Relevant footnotes:
  • F1: Sale was automatic to cover tax withholding for RSU vesting.
  • F2: Multiple trade prices; weighted average reported (full breakdown available on request).
  • F3: These securities were RSUs (each RSU converts to one share upon vesting).
  • F4: Filing notes the Reporting Person acquired 4,000 shares under the 2024 ESPP on May 20, 2026.
• Transaction type: Reported as a sale (S) to cover taxes — routine and administrative (code F-type activity).

Context

• This was a small, routine tax-withholding sale tied to RSU vesting, common when equity awards vest. Such transactions typically reflect administrative tax settlement rather than a directional bet on the company.
• For retail investors, purchases by insiders may be more informative about confidence than routine withholding sales; this filing does not indicate a substantive change in insider ownership policy.